{
  "main_header": {
    "sid": 1244485,
    "name": "Frequency Therapeutics, Inc.",
    "stock_name": "Frequency Therapeutics, Inc.",
    "full_name": "Frequency Therapeutics, Inc.",
    "name_url": "stocks-analysis/frequency-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "6.81",
    "chg": 1.53,
    "chgp": "28.98%",
    "dir": 1,
    "prev_price": "5.28",
    "mcapval": "189.80",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US35803L1089",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "356.34 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/frequency-therapeutics-inc-1244485-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Frequency Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-frequency-therapeutics-inc-overvalued-or-undervalued-3543931",
        "imagepath": "",
        "date": "2025-09-20 18:33:01",
        "description": "As of 18 March 2025, the valuation grade for Frequency Therapeutics, Inc. has moved from does not qualify to risky, indicating a deteriorating outlook. The company appears to be overvalued given its financial metrics, including a Price to Book Value of 0.98, an EV to Sales ratio of 4.99, and an ROE of -62.91%. In comparison to peers, Frequency Therapeutics has a significantly negative EV to EBITDA of -0.26, while Surrozen, Inc. shows a more favorable EV to EBITDA of -0.3289.\n\nThe stock has underperformed against the S&P 500, with a year-to-date return of -12.74% compared to the index's 12.22%, and over the past five years, it has declined by 97.34% while the S&P 500 gained 96.61%. This stark contrast reinforces the view that Frequency Therapeutics is currently overvalued...."
      }
    ],
    "total": 6,
    "sid": "1244485",
    "stock_news_url": "https://www.marketsmojo.com/news/frequency-therapeutics-inc-1244485"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Frequency Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:33:01

As of 18 March 2025, the valuation grade for Frequency Therapeutics, Inc. has moved from does not qualify to risky, indicating a deteriorating outlook. The company appears to be overvalued given its financial metrics, including a Price to Book Value of 0.98, an EV to Sales ratio of 4.99, and an ROE of -62.91%. In comparison to peers, Frequency Therapeutics has a significantly negative EV to EBITDA of -0.26, while Surrozen, Inc. shows a more favorable EV to EBITDA of -0.3289. The stock has underperformed against the S&P 500, with a year-to-date return of -12.74% compared to the index's 12.22%, and over the past five years, it has declined by 97.34% while the S&P 500 gained 96.61%. This stark contrast reinforces the view that Frequency Therapeutics is currently overvalued....

Read More

View All News